A new joint venture between London-based Glaxosmithkline plc. (GSK) and Google's parent company, Mountain View, Calif.-based Alphabet Inc., will evaluate bioelectronics medicine to combat chronic conditions, with Type 2 diabetes expected as a potential focus of initial research.